Trial Profile
A Single Arm, Open-Label, Phase 2 Trial Investigating Nitric Oxide-Inhalation (NO) in Nontuberculous Mycobacteria (NTM) Patients with Mycobacterium Abscessus Complex (MABSC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Aug 2019
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications Mycobacterium avium complex infections; Nontuberculous mycobacterium infections
- Focus Adverse reactions
- Acronyms NO-NTM Abscessus
- 15 Jul 2019 According to a Beyond Air media release, the company has changed its name from AIT Therapeutics to Beyond Air.
- 29 May 2019 According to an AIT Therapeutics media release, results from the study have been published in the Journal of Cystic Fibrosis.
- 29 May 2019 Results presented in an AIT Therapeutics media release.